image
Healthcare - Medical - Devices - NASDAQ - US
$ 303.15
0.451 %
$ 21.3 B
Market Cap
54.72
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one PODD stock under the worst case scenario is HIDDEN Compared to the current market price of 303 USD, Insulet Corporation is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one PODD stock under the base case scenario is HIDDEN Compared to the current market price of 303 USD, Insulet Corporation is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one PODD stock under the best case scenario is HIDDEN Compared to the current market price of 303 USD, Insulet Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart PODD

image
$330.0$330.0$320.0$320.0$310.0$310.0$300.0$300.0$290.0$290.0$280.0$280.0$270.0$270.0$260.0$260.0$250.0$250.0$240.0$240.0$230.0$230.0Jan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 Jun
FINANCIALS
2.07 B REVENUE
22.07%
309 M OPERATING INCOME
40.41%
418 M NET INCOME
102.76%
430 M OPERATING CASH FLOW
195.33%
-146 M INVESTING CASH FLOW
-22.45%
-28.1 M FINANCING CASH FLOW
-106.62%
569 M REVENUE
-4.77%
88.8 M OPERATING INCOME
-18.76%
35.4 M NET INCOME
-64.85%
63.8 M OPERATING CASH FLOW
-56.80%
-15.7 M INVESTING CASH FLOW
76.91%
278 M FINANCING CASH FLOW
1429.19%
Balance Sheet Insulet Corporation
image
Current Assets 1.89 B
Cash & Short-Term Investments 953 M
Receivables 366 M
Other Current Assets 572 M
Non-Current Assets 1.2 B
Long-Term Investments 0
PP&E 723 M
Other Non-Current Assets 473 M
30.88 %11.84 %18.54 %23.42 %15.33 %Total Assets$3.1b
Current Liabilities 528 M
Accounts Payable 19.8 M
Short-Term Debt 83.8 M
Other Current Liabilities 425 M
Non-Current Liabilities 1.35 B
Long-Term Debt 1.3 B
Other Non-Current Liabilities 51.6 M
4.47 %22.64 %69.08 %Total Liabilities$1.9b
EFFICIENCY
Earnings Waterfall Insulet Corporation
image
Revenue 2.07 B
Cost Of Revenue 626 M
Gross Profit 1.45 B
Operating Expenses 1.14 B
Operating Income 309 M
Other Expenses -109 M
Net Income 418 M
3b3b2b2b2b2b1b1b500m500m002b(626m)1b(1b)309m109m418mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
69.79% GROSS MARGIN
69.79%
14.91% OPERATING MARGIN
14.91%
20.19% NET MARGIN
20.19%
34.52% ROE
34.52%
13.55% ROA
13.55%
16.28% ROIC
16.28%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Insulet Corporation
image
350m350m300m300m250m250m200m200m150m150m100m100m50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 418 M
Depreciation & Amortization 80.8 M
Capital Expenditures -125 M
Stock-Based Compensation 69.3 M
Change in Working Capital 0
Others 0
Free Cash Flow 305 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Insulet Corporation
image
Wall Street analysts predict an average 1-year price target for PODD of $268 , with forecasts ranging from a low of $230 to a high of $322 .
PODD Lowest Price Target Wall Street Target
230 USD -24.13%
PODD Average Price Target Wall Street Target
268 USD -11.67%
PODD Highest Price Target Wall Street Target
322 USD 6.22%
Price
Max Price Target
Min Price Target
Average Price Target
340340320320300300280280260260240240220220200200180180Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 13
6. Ownership
Insider Ownership Insulet Corporation
image
Sold
0-3 MONTHS
5.54 M USD 6
3-6 MONTHS
3.97 M USD 2
6-9 MONTHS
1.56 M USD 3
9-12 MONTHS
4.14 M USD 5
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
20.6 K USD 1
9-12 MONTHS
7. News
Insulet to Share Additional Evidence Demonstrating the Impact of Omnipod® 5 on Improved Health Outcomes at the American Diabetes Association 85th Scientific Sessions ACTON, Mass.--(BUSINESS WIRE)--Insulet to Share Additional Evidence Demonstrating the Impact of Omnipod 5 on Improved Health Outcomes at the American Diabetes Association Conference. businesswire.com - 2 weeks ago
Here's Why You Should Retain PODD Stock in Your Portfolio Now Insulet's Omnipod 5 gains traction with global expansion and rising Type 2 adoption despite economic and competitive hurdles. zacks.com - 3 weeks ago
Insulet's Omnipod® 5 App for iPhone with Dexcom G7 Integration Now Available to all U.S. Users ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology, is excited to announce that the Omnipod® 5 App for iPhone is now compatible with the Dexcom G7 Continuous Glucose Monitoring (CGM) System. With this latest integration, the Omnipod 5 Automated Insulin Delivery (AID) System combines the benefits of tubeless AID and Dexcom's latest diabetes management technology, all conveniently controlled from an iPhone. "This integration re. businesswire.com - 3 weeks ago
3 Medical Technology Stocks Outperforming in 2025 As the broader market stages a sharp rebound from its April lows, several sectors, industries, and stocks have quietly emerged as leaders. Among them, the medical technology industry, known for its innovation and growth potential, has stood out. marketbeat.com - 3 weeks ago
Here's Why Insulet (PODD) is a Strong Growth Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. zacks.com - 4 weeks ago
S&P 500 Wraps Up Best May Since 1990: 5 Top Stocks in the ETF SPY jumped 6.3% in May, the most in decades, led by standout gains in NRG, STX, CEG, PODD and MCHP amid easing trade fears. zacks.com - 4 weeks ago
Insulet Gains 78.5% in a Year: What's Driving the Stock? PODD's shares rise on the back of Omnipod 5's growth, global expansion, and strong Q1 2025 gains despite rising operating costs and macro headwinds. zacks.com - 1 month ago
Insulet to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 in Miami on Tuesday, June 10, 2025 at 9:20 a.m. (Eastern Time). To listen to the live audio webcast of the presentation, please visit investors.insulet.com/events. A replay of the webcast will also be available followin. businesswire.com - 1 month ago
4 Medical Product Stocks to Watch From a Challenging Industry The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR reflect the favorable fundamentals. zacks.com - 1 month ago
Here's Why Insulet (PODD) is a Strong Momentum Stock Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. zacks.com - 1 month ago
Why Insulet (PODD) is a Top Growth Stock for the Long-Term Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. zacks.com - 1 month ago
Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer Insulet Corporation's NASDAQ: PODD recent outperformance has caught investors' attention and has earned it a designation as a top performer on the S&P 500. marketbeat.com - 1 month ago
8. Profile Summary

Insulet Corporation PODD

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 21.3 B
Dividend Yield 0.00%
Description Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Contact 100 Nagog Park, Acton, MA, 01720 https://www.insulet.com
IPO Date May 15, 2007
Employees 3900
Officers Ms. Ashley A. McEvoy Chief Executive Officer, President & Director Mr. Amit Guliani Interim Chief Technology Officer & Group Vice President of Customer-Facing Software Engineering June Lazaroff Senior Director of Investor Relations Ms. Laetitia Cousin Senior Vice President of Regulatory Affairs, Quality Assurance & Compliance Ms. Angela Geryak Wiczek Senior Director of Corporate Communications Ms. Ana Maria Chadwick Executive Vice President, Chief Financial Officer & Treasurer Ms. Lauren Budden Group Vice President, Chief Accounting Officer & Controller Mr. John Wodick Kapples J.D. Senior Vice President & General Counsel Mr. Eric Benjamin Executive Vice President, Chief Product & Customer Experience Officer Mr. Prem Singh Senior Vice President of Global Operations